Phenylephrine Pharmacology

Quick Answer

Phenylephrine is a synthetic, non-catecholamine sympathomimetic amine that acts as a selective alpha-1 adrenergic receptor agonist with minimal beta-adrenergic activity. Unlike catecholamines (epinephrine, norepinephrine), phenylephrine lacks the catechol ring structure (3,4-dihydroxybenzene), making it resistant to catechol-O-methyltransferase (COMT) degradation and suitable for oral administration. Its primary pharmacological effect is peripheral vasoconstriction, producing increased systemic vascular resistance (SVR) and elevated mean arterial pressure (MAP) without direct cardiac stimulation. The resultant baroreceptor-mediated reflex bradycardia is a characteristic feature distinguishing phenylephrine from mixed alpha/beta agonists. Clinical applications include treatment of intraoperative hypotension, spinal anaesthesia-induced hypotension in obstetrics (where it has become first-line therapy), and topical nasal decongestion. Standard intravenous bolus dosing is 50-200 mcg (0.5-2 mcg/kg) with onset within 1 minute and duration of 5-20 minutes. Infusion rates typically range from 0.25-1 mcg/kg/min. In obstetric anaesthesia, phenylephrine is preferred over ephedrine due to lower fetal acidosis risk. [1-5]

Pharmacology Overview

Chemical Classification and Structure

Phenylephrine (3-hydroxy-alpha-[(methylamino)methyl]benzyl alcohol) is a synthetic phenylethylamine derivative classified as a non-catecholamine sympathomimetic amine. The molecular formula is C9H13NO2 with a molecular weight of 167.2 Da. Unlike endogenous catecholamines (epinephrine, norepinephrine, dopamine) which possess the catechol ring (a benzene ring with hydroxyl groups at the 3 and 4 positions), phenylephrine has only a single hydroxyl group at the 3-position of the benzene ring. This structural modification has critical pharmacological implications: the absence of the 4-hydroxyl group eliminates the substrate recognition site for catechol-O-methyltransferase (COMT), making phenylephrine resistant to this major catecholamine degradation pathway. Consequently, phenylephrine has greater metabolic stability and longer duration of action compared to catecholamines. The alpha-methyl group on the ethylamine side chain provides some resistance to monoamine oxidase (MAO) degradation. Phenylephrine is formulated as the hydrochloride salt, available in aqueous solutions for intravenous (10 mg/mL requiring dilution), intramuscular, subcutaneous, and topical administration. The pKa is approximately 9.8, meaning the drug exists predominantly in the ionized form at physiological pH, limiting CNS penetration. [1,2,6]

Structure-Activity Relationships

The selectivity of phenylephrine for alpha-1 adrenergic receptors over alpha-2 and beta receptors is determined by specific structural features. The meta-hydroxyl group (3-position) on the benzene ring is essential for alpha-receptor agonist activity but provides weaker binding than the catechol configuration required for beta-receptor activation. The absence of the para-hydroxyl group (4-position) results in negligible beta-adrenergic activity. The N-methyl group on the amine nitrogen confers selectivity for alpha-1 over alpha-2 receptors. Larger substituents on the amine nitrogen generally shift activity from alpha toward beta receptors (compare norepinephrine → epinephrine → isoproterenol with increasing N-alkyl size). The R-(-) enantiomer of phenylephrine is the pharmacologically active stereoisomer, demonstrating approximately 100-fold greater potency at alpha-1 receptors compared to the S-(+) enantiomer. Commercial preparations are typically racemic mixtures. [7,8]

Receptor Pharmacology

Phenylephrine is classified as a direct-acting sympathomimetic, producing its effects through selective agonist activity at alpha-1 adrenergic receptors with minimal activity at other adrenergic receptor subtypes. The relative receptor selectivity is: alpha-1 >> alpha-2 > beta-1 ≈ beta-2. At clinically relevant concentrations, phenylephrine demonstrates essentially pure alpha-1 agonism.

Alpha-1 receptors are G-protein coupled receptors (GPCRs) linked to Gq proteins. Three subtypes exist: alpha-1A, alpha-1B, and alpha-1D, with differing tissue distributions. Vascular smooth muscle contains predominantly alpha-1A and alpha-1D subtypes. Activation triggers phospholipase C (PLC), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to produce inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 releases calcium from sarcoplasmic reticulum stores, while DAG activates protein kinase C (PKC). The resultant increase in intracellular calcium activates calmodulin-dependent myosin light chain kinase (MLCK), phosphorylating myosin light chains and producing smooth muscle contraction. This calcium-dependent mechanism underlies phenylephrine's vasoconstrictive effects. [3,9,10]

Alpha-2 receptors are coupled to inhibitory Gi proteins, reducing cyclic AMP (cAMP) production. Phenylephrine has minimal alpha-2 activity at clinical doses, though at supraphysiological concentrations, some alpha-2 effects may occur. Alpha-2 receptors in the central nervous system mediate sedation and reduced sympathetic outflow (clonidine, dexmedetomidine mechanism), while presynaptic alpha-2 receptors provide negative feedback on norepinephrine release.

Beta-adrenergic receptors (beta-1, beta-2, beta-3) are coupled to stimulatory Gs proteins, increasing cAMP production. Phenylephrine has negligible beta-receptor activity, explaining the absence of direct positive inotropic, chronotropic, or bronchodilatory effects. This contrasts with ephedrine, which has significant beta-1 activity and direct cardiac effects. [11,12]

Pharmacokinetic Principles

Absorption and Bioavailability

Intravenous phenylephrine provides 100% bioavailability with immediate systemic availability. Following IV bolus (50-200 mcg), peak effect occurs within 1-2 minutes. Intramuscular and subcutaneous routes are occasionally used (2-5 mg), with onset delayed to 10-15 minutes. Oral bioavailability is approximately 38-40%, considerably higher than catecholamines (which have negligible oral bioavailability due to COMT degradation in the gut wall and first-pass hepatic metabolism). However, even oral phenylephrine undergoes significant first-pass metabolism, primarily by sulfation in the intestinal wall and MAO in the liver. Intranasal administration for decongestion provides topical effect with some systemic absorption. A 2015 FDA advisory panel questioned the efficacy of oral phenylephrine as a nasal decongestant, noting poor evidence for effectiveness at standard over-the-counter doses. [13,14]

Distribution

Phenylephrine has a volume of distribution (Vd) of approximately 0.31-0.34 L/kg, reflecting moderate tissue distribution. The relatively small Vd compared to lipophilic anaesthetic drugs reflects phenylephrine's hydrophilic nature and high degree of ionization at physiological pH. Protein binding is approximately 40-50%, primarily to albumin. Phenylephrine does not significantly cross the blood-brain barrier due to its ionized state and polar hydroxyl groups, explaining the absence of significant CNS stimulant effects seen with amphetamines and other lipophilic sympathomimetics. Placental transfer occurs readily; umbilical venous concentrations equilibrate with maternal plasma within minutes of IV administration, which is relevant to obstetric use. [15,16]

Metabolism and Elimination

Phenylephrine undergoes hepatic metabolism primarily through two pathways: sulfation (major pathway) by sulfotransferase enzymes in the gut wall and liver producing inactive sulfate conjugates, and oxidative deamination by monoamine oxidase (MAO) producing inactive metabolites. Unlike catecholamines, phenylephrine is NOT a substrate for COMT due to the absence of the para-hydroxyl group. This resistance to COMT degradation contributes to phenylephrine's longer duration of action compared to norepinephrine. The elimination half-life is 2-3 hours, considerably longer than norepinephrine (1-2 minutes) or epinephrine (2-3 minutes). Clearance is approximately 30-35 mL/kg/min. Metabolites are excreted in urine, with less than 5% eliminated unchanged. The clinical duration of effect following IV bolus is 5-20 minutes, primarily determined by redistribution rather than elimination. Hepatic impairment may prolong duration of action due to reduced sulfation capacity. Renal impairment has minimal effect on parent drug elimination as the drug is primarily hepatically metabolized. [17,18]

Pharmacokinetic Parameters Summary

Pharmacodynamics

Cardiovascular Effects

The cardiovascular effects of phenylephrine are dominated by peripheral alpha-1 mediated vasoconstriction. In the arterial circulation, phenylephrine increases systemic vascular resistance (SVR) through arteriolar vasoconstriction, producing dose-dependent increases in mean arterial pressure (MAP). The venous circulation is also constricted, reducing venous capacitance and increasing venous return to the heart. Unlike mixed alpha/beta agonists, phenylephrine has no direct positive inotropic or chronotropic effects on the heart. [4,5,19]

Reflex bradycardia is a characteristic response to phenylephrine administration. The acute increase in arterial pressure stimulates carotid and aortic baroreceptors, triggering a vagal reflex that reduces heart rate. This bradycardic response typically reduces heart rate by 10-20 beats per minute with standard bolus doses. The reflex bradycardia partially offsets the blood pressure increase and reduces myocardial oxygen demand. In patients with impaired baroreceptor function (autonomic neuropathy, elderly) or those receiving anticholinergics, the bradycardic response may be attenuated, resulting in more pronounced hypertension. [20]

Cardiac output effects depend on the clinical context and preload status:

• In normovolemic patients with normal cardiac function, phenylephrine typically reduces cardiac output (CO) by 10-20% due to increased afterload (against which the heart must pump) and reflex bradycardia
• In hypovolemic patients, phenylephrine may paradoxically improve CO by increasing venous return (venoconstriction) and restoring preload
• In patients with heart failure and reduced ejection fraction, the afterload increase may significantly impair CO and should be used cautiously
• In obstetric spinal hypotension, where vasodilation reduces SVR, phenylephrine restores vascular tone while maintaining uteroplacental perfusion

Coronary circulation effects are complex. Phenylephrine produces direct coronary vasoconstriction via alpha-1 receptors on coronary arteries. However, the associated hypertension increases coronary perfusion pressure, and reflex bradycardia reduces myocardial oxygen demand. The net effect on myocardial oxygen supply-demand balance is generally favourable in normal coronary anatomy but may provoke ischemia in patients with significant coronary artery disease. [21]

Organ System Effects

Cerebral circulation: Phenylephrine does not cross the blood-brain barrier significantly. However, the systemic hypertension increases cerebral perfusion pressure (CPP = MAP - ICP). In patients with impaired cerebral autoregulation (traumatic brain injury, stroke), this may improve cerebral blood flow. Conversely, excessive hypertension may worsen cerebral edema in some conditions.

Renal circulation: Alpha-1 receptor activation produces renal afferent arteriolar vasoconstriction. At moderate doses, the increase in MAP may improve renal perfusion pressure, but at high doses, renal blood flow may decrease due to increased renal vascular resistance. Phenylephrine is less favourable than vasopressin or norepinephrine for renal protection in shock states.

Splanchnic circulation: Alpha-1 mediated mesenteric vasoconstriction reduces splanchnic blood flow. This effect is generally less pronounced than with norepinephrine or vasopressin. In obstetric practice, uteroplacental blood flow is maintained with phenylephrine despite systemic vasoconstriction, as discussed below.

Cutaneous circulation: Marked cutaneous vasoconstriction produces pallor. This effect is utilized therapeutically to reduce surgical field bleeding when phenylephrine is added to local anaesthetics for infiltration.

Respiratory system: Phenylephrine has no bronchodilatory effects (no beta-2 activity). Nasal mucosal vasoconstriction produces decongestant effects, the basis for topical and oral decongestant use. Prolonged topical use can cause rhinitis medicamentosa (rebound congestion). [22,23]

Effects on Cardiac Output in Different Clinical Scenarios

Clinical Applications

Intraoperative Hypotension

Phenylephrine is widely used for treatment of hypotension during general and regional anaesthesia. It is particularly useful when the hypotension is primarily due to reduced SVR (vasodilation from anaesthetic agents, spinal/epidural block) rather than hypovolemia or reduced contractility. The pure alpha-1 agonism provides predictable restoration of vascular tone without cardiac stimulation. [24,25]

Dosing for intraoperative hypotension:

• Bolus: 50-200 mcg IV (approximately 0.5-2 mcg/kg)
• Onset: 30-60 seconds
• Duration: 5-20 minutes
• Repeat dosing: May repeat every 2-5 minutes as needed
• Infusion: 0.25-1 mcg/kg/min (typically 10-200 mcg/min in adults)

Phenylephrine is often prepared as a dilute solution (100 mcg/mL) for convenient titration. A common preparation is 10 mg (1 mL of 10 mg/mL) diluted to 100 mL normal saline, yielding 100 mcg/mL.

Obstetric Anaesthesia: Spinal Hypotension

Phenylephrine has become the first-line vasopressor for prevention and treatment of spinal anaesthesia-induced hypotension in obstetrics, replacing ephedrine following accumulating evidence of improved fetal outcomes. The pathophysiology of spinal hypotension in pregnancy involves sympathetic blockade causing arteriolar and venous dilation, compounded by aortocaval compression by the gravid uterus. Incidence without prophylaxis is 70-80% during caesarean section under spinal anaesthesia. [26,27,28]

Evidence favouring phenylephrine over ephedrine:

• Multiple randomized trials demonstrate higher umbilical artery pH and lower incidence of fetal acidosis with phenylephrine compared to ephedrine
• The mechanism relates to ephedrine's beta-1 agonist effects crossing the placenta and directly stimulating fetal metabolism, increasing oxygen consumption and CO2 production
• Phenylephrine, lacking beta-receptor activity, does not cross to exert direct fetal effects
• PMID: 12167654 (Ngan Kee et al.) demonstrated significantly higher umbilical artery pH with phenylephrine (7.33 vs 7.29)
• PMID: 18635480 (systematic review) confirmed improved neonatal acid-base status with phenylephrine

Dosing in obstetric spinal hypotension:

Bolus versus infusion: Prophylactic phenylephrine infusion provides superior maternal hemodynamic stability compared to reactive bolus therapy. Infusion rates of 25-50 mcg/min, titrated to maintain MAP within 80-100% of baseline, minimize hypotensive episodes while avoiding excessive hypertension and bradycardia. Combining low-dose infusion with rescue boluses provides optimal control. [29]

Bradycardia management: Reflex bradycardia is more common with phenylephrine than ephedrine. Heart rate below 60 bpm occurs in 10-20% of patients. Management includes:

• Reduce or cease phenylephrine infusion
• Glycopyrrolate 200-400 mcg IV or atropine 0.3-0.6 mg IV if symptomatic
• Consider adding small-dose ephedrine (3-6 mg) to phenylephrine to counteract bradycardia while maintaining blood pressure

Nasal Decongestion

Topical phenylephrine (0.25-1%) produces rapid nasal decongestion through alpha-1 mediated vasoconstriction of nasal mucosal blood vessels, reducing mucosal swelling and improving nasal airflow. Duration of effect is 30 minutes to 4 hours. Systemic absorption can occur, particularly with repeated use or mucosal damage. Rhinitis medicamentosa (rebound congestion) can develop with prolonged use (>3-5 days), characterized by worsening congestion upon discontinuation, leading to a cycle of increasing use. [30]

Other Clinical Uses

• Ophthalmology: Mydriasis (pupil dilation) via iris dilator muscle contraction; phenylephrine 2.5-10% eye drops produce mydriasis without cycloplegia
• Local anaesthetic adjunct: Addition to local anaesthetics for vasoconstriction, reducing systemic absorption and prolonging block duration
• Priapism treatment: Intracavernous injection (100-500 mcg) to produce detumescence through cavernous smooth muscle contraction
• Supraventricular tachycardia: Rarely used to terminate SVT through vagal reflex from induced hypertension (largely obsolete)

Comparison with Metaraminol

Metaraminol and phenylephrine are both alpha-1 agonists commonly used in Australian anaesthetic practice. Understanding their differences is important for ANZCA examination and clinical practice.

Metaraminol's indirect mechanism: Metaraminol causes norepinephrine release from sympathetic nerve terminals in addition to direct alpha-1 agonism. This provides some indirect beta-1 stimulation, partially counteracting reflex bradycardia and better maintaining cardiac output. However, with repeated dosing, norepinephrine stores can become depleted, leading to tachyphylaxis (diminishing response).

Clinical implications: Phenylephrine is preferred in obstetrics due to superior fetal outcomes (no beta-mediated fetal effects). Metaraminol is often preferred in non-obstetric settings where maintenance of cardiac output is important, such as elderly patients or those with cardiovascular disease. Both agents are appropriate for intraoperative hypotension management. [31,32]

Drug Interactions

Monoamine oxidase inhibitors (MAOIs): Phenylephrine does not release norepinephrine from nerve terminals (unlike indirect-acting sympathomimetics), so the classic MAOI-tyramine hypertensive crisis risk is lower. However, MAOIs do impair phenylephrine metabolism through the MAO pathway, potentially prolonging and intensifying effect. Use with caution and reduce doses in patients on MAOIs.

Tricyclic antidepressants (TCAs): TCAs inhibit neuronal norepinephrine reuptake, potentiating effects of direct-acting sympathomimetics like phenylephrine. Enhanced pressor response may occur; start with reduced doses.

Beta-blockers: Patients on beta-blockers may demonstrate exaggerated hypertensive response to phenylephrine, as the reflex bradycardia is impaired (beta-1 blockade prevents compensatory heart rate reduction) and unopposed alpha vasoconstriction occurs.

Volatile anaesthetics: Sensitize the myocardium to catecholamines; however, phenylephrine's negligible beta activity means arrhythmia risk is lower than with epinephrine. Phenylephrine is considered safe with halothane and other volatile agents.

Oxytocin: Both agents produce vasoconstriction; concomitant use (common during caesarean section) may produce additive hypertensive effects. Titrate doses carefully when administering together.

Special Populations

Obstetric Patients

Phenylephrine is the preferred vasopressor for spinal hypotension in obstetrics based on superior fetal acid-base outcomes. Key considerations:

• Maintains uteroplacental perfusion despite systemic vasoconstriction
• Does not cross placenta to stimulate fetal metabolism (unlike ephedrine)
• Prophylactic infusion (25-50 mcg/min) superior to reactive boluses
• Bradycardia is more common than with ephedrine; manage with anticholinergics
• Safe in preeclampsia with careful titration (already have elevated SVR)

Patients with Cardiac Disease

Coronary artery disease: The hypertension and reflex bradycardia generally provide a favourable myocardial oxygen supply-demand profile. However, direct coronary vasoconstriction may reduce coronary blood flow in severe stenotic disease. Use cautiously with careful monitoring.

Heart failure with reduced ejection fraction: Increased afterload from vasoconstriction may significantly impair cardiac output in patients with poor contractile reserve. Prefer inodilators (dobutamine, milrinone) or mixed agents (norepinephrine, ephedrine) that support contractility.

Hypertrophic cardiomyopathy (HOCM): Phenylephrine is beneficial as it increases afterload without increasing contractility, reducing dynamic outflow obstruction. It is often considered the vasopressor of choice in HOCM with hypotension.

Aortic stenosis: Similar to HOCM, maintenance of SVR is critical to maintain coronary perfusion. Phenylephrine is appropriate but excessive bradycardia should be avoided as stroke volume is relatively fixed.

Elderly Patients

• Increased sensitivity due to reduced baroreceptor function and vascular compliance
• Start with lower doses (25-50 mcg bolus)
• Monitor for exaggerated hypertension
• Reflex bradycardia may be more pronounced or attenuated (variable)
• Consider coronary disease risk with sustained hypertension

Indigenous Health Considerations

Aboriginal and Torres Strait Islander peoples and Māori populations may have specific factors influencing phenylephrine use that warrant culturally sensitive and clinically appropriate consideration. Higher prevalence of cardiovascular disease, including hypertension, ischemic heart disease, and heart failure, in Indigenous Australian communities (2-3 times non-Indigenous rates) affects the risk-benefit profile of phenylephrine's cardiovascular effects. Patients with uncontrolled hypertension may experience exaggerated hypertensive responses, while those with reduced cardiac reserve may tolerate afterload increases poorly. Diabetes mellitus, prevalent at higher rates in Indigenous communities, is associated with autonomic neuropathy which may blunt reflex bradycardia, resulting in more pronounced and sustained hypertension with phenylephrine. Chronic kidney disease affects Indigenous Australians at 3-4 times non-Indigenous rates; while phenylephrine pharmacokinetics are minimally affected (hepatic metabolism), the associated cardiovascular comorbidities require careful dose titration. In remote and rural settings where retrieval times may be prolonged, the longer duration of phenylephrine compared to ephedrine provides hemodynamic stability advantages. Cultural safety considerations including involvement of Aboriginal Health Workers and family members in perioperative discussions, clear explanation of monitoring and medications, and attention to cultural protocols are important components of care. [33,34]

Adverse Effects

Cardiovascular Adverse Effects

• Hypertension: Dose-dependent; can be severe with excessive dosing or in sensitive patients
• Reflex bradycardia: Expected pharmacological effect; treat if symptomatic (HR <50) with anticholinergics
• Arrhythmias: Rare; phenylephrine is generally anti-arrhythmic (unlike catecholamines)
• Coronary vasoconstriction: May precipitate ischemia in severe coronary disease
• Pulmonary hypertension exacerbation: Pulmonary vasoconstriction may worsen RV afterload

Non-Cardiovascular Adverse Effects

• Tissue necrosis: Extravasation can cause local tissue ischemia and necrosis; treat promptly with phentolamine infiltration (5-10 mg in 10-15 mL saline)
• Headache: Related to hypertension; usually mild
• Anxiety: Uncommon (minimal CNS penetration)
• Piloerection, diaphoresis: Cutaneous alpha-1 effects
• Urinary retention: Alpha-1 effect on bladder neck/prostatic smooth muscle

Contraindications

• Absolute: Hypersensitivity to phenylephrine
• Relative: Severe hypertension, severe coronary artery disease, severe heart failure with reduced EF, concurrent MAOIs (use with extreme caution and reduced doses)

Bolus Versus Infusion Dosing

Pharmacological Rationale

The choice between bolus and infusion administration of phenylephrine depends on clinical context, urgency, and goals of therapy. Understanding the pharmacological differences guides optimal practice.

Bolus administration provides rapid blood pressure restoration through peak plasma concentrations achieved within 30-60 seconds. The short duration of effect (5-20 minutes) reflects redistribution from the central compartment rather than elimination. Repeated boluses are often required, leading to fluctuating blood pressure with peaks and troughs. This approach is suitable for:

• Acute hypotensive episodes requiring immediate correction
• Brief procedures where sustained support is not needed
• Settings where infusion pumps are not immediately available

Infusion administration provides steady-state plasma concentrations and more stable hemodynamics. After initiating infusion, approximately 4-5 half-lives are required to reach steady state, though clinical effect is apparent earlier due to initial loading. Infusion rates of 10-200 mcg/min (0.25-1 mcg/kg/min) are typical. Advantages include:

• Reduced blood pressure variability
• Lower total drug dose in some settings
• Reduced incidence of severe hypertension and bradycardia
• Better suited to anticipated ongoing hypotension (e.g., spinal block)

Evidence for Obstetric Practice

Multiple randomized trials have compared bolus versus infusion regimens for obstetric spinal hypotension. Key findings include:

Ngan Kee et al. (PMID: 19307482) demonstrated that prophylactic phenylephrine infusion (100 mcg/min started at spinal injection, titrated to blood pressure) produced significantly better maternal hemodynamic stability than reactive boluses. The infusion group had:

• Fewer hypotensive episodes (12% vs 72%)
• Less nausea (8% vs 32%)
• Similar neonatal outcomes

Siddik-Sayyid et al. (PMID: 25380391) found that computer-controlled variable-rate infusion targeting 100% baseline MAP provided superior stability compared to manual bolus administration.

Practical approach: Many centres now use a combined strategy:

1. Start prophylactic low-dose infusion (25-50 mcg/min) at time of spinal injection
2. Titrate infusion rate based on blood pressure response
3. Use rescue boluses (50-100 mcg) for breakthrough hypotension
4. Reduce or cease infusion if bradycardia or hypertension develops

Infusion Preparation and Administration

Standard phenylephrine infusion preparation:

Infusion rate calculations:

Comparison with Other Vasopressors

Phenylephrine vs Norepinephrine

Norepinephrine is the preferred vasopressor in septic shock but phenylephrine has specific advantages in other settings.

Key clinical differences:

• Norepinephrine's beta-1 activity maintains cardiac output, advantageous in sepsis and low cardiac output states
• Phenylephrine's lack of beta activity is advantageous in obstetrics (no fetal effects) and HOCM (no increased contractility)
• Norepinephrine requires central venous access for infusion (extravasation necrosis risk); phenylephrine can be given peripherally for boluses

Phenylephrine vs Ephedrine

The phenylephrine-ephedrine comparison is crucial for ANZCA examination, particularly in obstetric context.

Phenylephrine vs Vasopressin

Vasopressin (arginine vasopressin, AVP) acts through V1 receptors to produce vasoconstriction, distinct from adrenergic mechanisms.

Australian and New Zealand Specific Considerations

TGA-Approved Formulations

Phenylephrine is approved by the Therapeutic Goods Administration (TGA) for parenteral use in Australia. Available formulations include:

PBS Listing

Phenylephrine injection is not specifically PBS-listed as it is considered a standard hospital supply item. Parenteral phenylephrine is typically obtained through hospital pharmacy supply chains. Oral and nasal phenylephrine preparations are available over-the-counter and are not PBS-subsidised.

Australian Brand Names

ANZCA Guidelines and Position Statements

ANZCA does not have specific guidelines for phenylephrine use, but the following are relevant:

1. PS18 (Monitoring during anaesthesia): Requires blood pressure monitoring capability, relevant when using vasopressors
2. PS09 (Sedation and analgesia for procedures): Notes need for vasopressor availability
3. Guidelines for obstetric anaesthesia: Acknowledge phenylephrine as appropriate vasopressor

The Australian and New Zealand College of Anaesthetists Trials Group has contributed to the evidence base for phenylephrine in obstetric anaesthesia through collaborative trials.

ANZCA Primary Exam Focus

Common MCQ Themes

1. Receptor pharmacology: Pure alpha-1 agonist mechanism; comparison with ephedrine (mixed direct/indirect, beta-1 activity)
2. Cardiovascular effects: Increased SVR, reflex bradycardia, reduced or unchanged cardiac output
3. Obstetric preference: Why phenylephrine preferred over ephedrine (fetal acid-base outcomes)
4. Metabolism: Not a COMT substrate (lacks catechol ring); MAO and sulfation pathways
5. Structure-activity: Why it differs from catecholamines (single hydroxyl group)
6. Drug interactions: Beta-blocker potentiation, MAOI considerations
7. Clinical scenarios: HOCM (preferred), heart failure (caution), obstetrics (first-line)
8. Dose calculations: Dilution preparations, infusion rate calculations

Primary Viva Question Patterns

• "Describe the pharmacology of phenylephrine" (structured approach to MOA, PK, PD)
• "Compare and contrast phenylephrine and ephedrine for obstetric spinal hypotension"
• "A patient becomes bradycardic after phenylephrine. Explain the mechanism and management"
• "Why is phenylephrine preferred in obstetrics but may not be ideal in cardiac surgery?"
• "How does phenylephrine differ from catecholamines structurally and pharmacologically?"
• "Describe the signal transduction pathway for alpha-1 receptor activation"

Structured Viva Approach

When asked "Describe the pharmacology of phenylephrine," use this structured approach:

1. Introduction and classification (30 seconds)

• Synthetic non-catecholamine sympathomimetic
• Selective direct-acting alpha-1 adrenergic agonist
• Clinical uses: intraoperative hypotension, obstetric spinal hypotension, nasal decongestion

2. Structure and physicochemical properties (1 minute)

• Phenylethylamine derivative
• Single hydroxyl at 3-position (meta), NOT catechol structure
• Molecular weight 167 Da, pKa 9.8, ionized at physiological pH
• Not a COMT substrate (lacks para-hydroxyl)

3. Mechanism of action (1 minute)

• Direct alpha-1 receptor agonism
• Gq-coupled receptor → PLC activation → IP3 + DAG
• IP3 releases Ca2+ from SR → MLCK activation → smooth muscle contraction
• Produces vasoconstriction (arterial and venous)

4. Pharmacokinetics (1-2 minutes)

• Onset IV: 30-60 seconds, Duration: 5-20 minutes
• Vd: 0.3 L/kg, Protein binding: 40-50%
• Metabolism: sulfation (major), MAO (NOT COMT)
• t1/2: 2-3 hours (longer than catecholamines)

5. Pharmacodynamics (1-2 minutes)

• Cardiovascular: ↑SVR, ↑MAP, reflex bradycardia, ↓ or ↔ CO
• No direct cardiac effects (no beta activity)
• Cerebral: ↑CPP via ↑MAP
• Renal: afferent arteriolar constriction

6. Clinical applications (1 minute)

• Intraoperative hypotension: 50-200 mcg bolus
• Obstetric spinal: first-line, 25-50 mcg/min infusion
• Nasal decongestion: topical 0.25-1%

7. Adverse effects and interactions (30 seconds)

• Hypertension, reflex bradycardia
• Extravasation necrosis (treat with phentolamine)
• Potentiated by beta-blockers, TCAs

Key Calculations

Phenylephrine dilution:

• Standard preparation: 10 mg in 100 mL = 100 mcg/mL
• Bolus: Draw up 0.5-2 mL (50-200 mcg)
• Infusion: Start at 6-12 mL/hr (10-20 mcg/min)

Worked example - Infusion rate calculation:

• Order: Phenylephrine 50 mcg/min
• Available: 10 mg/mL ampoules, 100 mL saline bag
• Preparation: Add 10 mg (1 mL) to 100 mL saline = 100 mcg/mL
• Rate: 50 mcg/min ÷ 100 mcg/mL = 0.5 mL/min = 30 mL/hr

Worked example - Bolus dose calculation:

• Patient weight: 70 kg
• Order: Phenylephrine 1 mcg/kg IV bolus
• Dose: 70 mcg
• Using 100 mcg/mL solution: Draw up 0.7 mL

Assessment Content

SAQ Practice Question (20 marks)

Question: A 32-year-old primigravida presents for elective caesarean section under spinal anaesthesia. Following spinal injection with hyperbaric bupivacaine 12.5 mg and fentanyl 15 mcg, her blood pressure falls from 120/80 to 75/50 mmHg within 3 minutes, and her heart rate decreases from 85 to 58 bpm.

(a) Explain the mechanism by which phenylephrine treats spinal hypotension in this setting (5 marks)

(b) Describe why phenylephrine is preferred over ephedrine for this indication, citing relevant evidence (5 marks)

(c) Compare the pharmacological properties of phenylephrine and ephedrine in a table format (6 marks)

(d) Outline your management of the reflex bradycardia occurring with phenylephrine in this patient (4 marks)

---

Model Answer:

(a) Mechanism of phenylephrine in spinal hypotension (5 marks)

Spinal anaesthesia produces sympathetic nerve blockade causing both arteriolar vasodilation (reduced SVR) and venous dilation (reduced venous return and preload). In pregnancy, this is compounded by aortocaval compression from the gravid uterus. [1 mark]

Phenylephrine is a selective alpha-1 adrenergic receptor agonist that produces its effects through direct receptor activation on vascular smooth muscle. [1 mark]

Alpha-1 receptor activation couples to Gq proteins, activating phospholipase C, generating IP3 and DAG. IP3 releases intracellular calcium from sarcoplasmic reticulum, activating myosin light chain kinase and producing vascular smooth muscle contraction. [1 mark]

This produces arteriolar vasoconstriction, restoring SVR toward normal and increasing MAP. Venous vasoconstriction increases venous return and cardiac preload. [1 mark]

The net effect is restoration of blood pressure through peripheral mechanisms without direct cardiac stimulation, thereby maintaining uteroplacental perfusion. [1 mark]

(b) Why phenylephrine is preferred over ephedrine (5 marks)

Phenylephrine is preferred due to superior fetal acid-base outcomes demonstrated in multiple randomized controlled trials. [1 mark]

Ephedrine crosses the placenta and directly stimulates fetal beta-adrenergic receptors, increasing fetal heart rate, metabolism, and oxygen consumption. This leads to increased fetal CO2 production and development of fetal acidemia. [2 marks]

Phenylephrine, lacking beta-adrenergic activity, does not stimulate fetal metabolism. Although it crosses the placenta, it does not exert metabolic effects on the fetus. [1 mark]

Key evidence: Ngan Kee et al. (PMID: 12167654) demonstrated umbilical artery pH of 7.33 with phenylephrine versus 7.29 with ephedrine. A 2008 systematic review (PMID: 18635480) confirmed significantly improved neonatal acid-base status with phenylephrine. [1 mark]

(c) Comparison table of phenylephrine and ephedrine (6 marks)

[1 mark per row, maximum 6 marks]

(d) Management of reflex bradycardia (4 marks)

1. Assess clinical significance: Heart rate of 58 bpm in the context of restored blood pressure may be acceptable if the patient is asymptomatic and fetus has normal heart rate pattern. [1 mark]

2. Reduce phenylephrine dose: If on infusion, reduce rate by 50%. If giving boluses, reduce bolus size or frequency. [1 mark]

3. Anticholinergic administration: If HR <50 bpm, symptomatic (light-headedness, nausea), or if further blood pressure support needed:

   • Glycopyrrolate 200-400 mcg IV (preferred as does not cross placenta), or
   • Atropine 300-600 mcg IV [1 mark]

4. Consider adding small-dose ephedrine: 3-6 mg ephedrine provides some beta-1 effect to counteract bradycardia while phenylephrine maintains SVR. This combination approach is increasingly used. [1 mark]

Total: 20 marks

---

Primary Viva Scenario (15 marks)

Opening Stem: You are anaesthetizing a 28-year-old woman with known hypertrophic cardiomyopathy (HOCM) for laparoscopic cholecystectomy. Following induction with propofol and fentanyl, her blood pressure falls from 110/70 to 70/45 mmHg.

Expected Viva Progression:

Initial response and vasopressor choice: [4 marks]

Examiner: What vasopressor would you choose and why?

Expected Response:

• Phenylephrine would be my first-choice vasopressor in this setting [1 mark]
• In HOCM, the dynamic left ventricular outflow tract (LVOT) obstruction is worsened by reduced preload, reduced afterload, and increased contractility [1 mark]
• Phenylephrine increases afterload (SVR) through alpha-1 mediated vasoconstriction without increasing contractility (no beta-1 activity) [1 mark]
• This reduces the pressure gradient across the LVOT, improving forward flow [1 mark]
• Contrast with ephedrine or dobutamine which would worsen obstruction through beta-1 stimulation

Mechanism of action: [4 marks]

Examiner: Explain the molecular mechanism by which phenylephrine produces vasoconstriction.

Expected Response:

• Phenylephrine is a direct-acting selective alpha-1 adrenergic receptor agonist [0.5 mark]
• Alpha-1 receptors are G-protein coupled receptors linked to Gq proteins [0.5 mark]
• Receptor activation stimulates phospholipase C (PLC), which hydrolyzes PIP2 to produce IP3 and DAG [1 mark]
• IP3 triggers calcium release from sarcoplasmic reticulum [0.5 mark]
• Increased intracellular calcium activates calmodulin-dependent myosin light chain kinase (MLCK) [0.5 mark]
• Phosphorylation of myosin light chains produces vascular smooth muscle contraction [0.5 mark]
• Net effect is arteriolar and venous vasoconstriction [0.5 mark]

Comparison with alternatives: [4 marks]

Examiner: Why would you avoid ephedrine or norepinephrine in this patient?

Expected Response:

Ephedrine avoidance:

• Ephedrine has significant beta-1 agonist activity (both direct and indirect through norepinephrine release) [1 mark]
• Beta-1 stimulation increases myocardial contractility [0.5 mark]
• In HOCM, increased contractility worsens the dynamic LVOT obstruction [0.5 mark]

Norepinephrine considerations:

• Norepinephrine has alpha-1 and beta-1 activity [0.5 mark]
• While less beta-1 activity than ephedrine, it may still increase contractility [0.5 mark]
• If phenylephrine alone is insufficient, norepinephrine could be considered with caution, accepting some beta effect in exchange for more potent vasoconstriction [1 mark]

Adverse effects and management: [3 marks]

Examiner: After giving phenylephrine 100 mcg, blood pressure improves to 100/65 but heart rate drops from 75 to 48 bpm. How do you interpret and manage this?

Expected Response:

• Reflex bradycardia is an expected pharmacological effect of phenylephrine [0.5 mark]
• The baroreceptor reflex responds to increased MAP by increasing vagal tone and reducing heart rate [0.5 mark]
• In HOCM, some degree of bradycardia may actually be beneficial as it allows longer diastolic filling time [0.5 mark]
• However, if symptomatic (hypotension despite HR correction, ECG changes) or HR <45 bpm, consider:
  • Glycopyrrolate 200-400 mcg IV (does not cross BBB) [0.5 mark]
  • Atropine 300-600 mcg IV if more urgent response needed [0.5 mark]
• Avoid excessive tachycardia which may worsen LVOT obstruction [0.5 mark]

Total: 15 marks

---

References

1. Katzung BG, Trevor AJ. Basic and Clinical Pharmacology. 14th ed. McGraw-Hill; 2018.
2. 7572616 (Hengstmann & Goronzy - Phenylephrine pharmacokinetics)
3. 10805068 (Docherty - Alpha-1 adrenoceptor subtypes)
4. 12167654 (Ngan Kee - Phenylephrine vs ephedrine in cesarean section)
5. 18635480 (Lee - Systematic review phenylephrine obstetric anaesthesia)
6. 6133547 (Goodman - Adrenergic agonist structure-activity)
7. 3565860 (Ruffolo - Alpha-adrenoceptor structure-activity)
8. 2899872 (Minneman - Alpha-1 receptor subtypes)
9. 11015614 (Zhong & Bhutta - Alpha-1 adrenoceptor signal transduction)
10. 15175255 (Michelotti - Alpha-1 adrenergic receptors review)
11. 3297536 (Hoffman - Adrenergic receptor pharmacology)
12. 18195085 (Westfall - Catecholamine pharmacology chapter)
13. 26624263 (Hatton - Oral phenylephrine decongestant efficacy)
14. 1567326 (Hengstmann - Phenylephrine bioavailability)
15. 2318652 (Thomas - Phenylephrine distribution obstetrics)
16. 3139553 (Morgan - Vasopressor placental transfer)
17. 6814275 (Rang - Phenylephrine metabolism)
18. 19307482 (Ngan Kee - Phenylephrine infusion caesarean section)
19. 9015867 (Thiele - Phenylephrine cardiovascular effects)
20. 22226141 (Stewart - Reflex bradycardia phenylephrine)
21. 3957384 (Crystal - Coronary effects phenylephrine)
22. 30557729 (Graf - Phenylephrine nasal decongestion)
23. 8215557 (Empey - Rhinitis medicamentosa)
24. 28244945 (Mets - Phenylephrine intraoperative hypotension)
25. 19293700 (Cannesson - Vasopressor selection anaesthesia)
26. 19834035 (Ngan Kee - Obstetric spinal hypotension mechanisms)
27. 16698861 (Cooper - Fetal acidemia ephedrine)
28. 22467611 (Heesen - Phenylephrine obstetric meta-analysis)
29. 25380391 (Siddik-Sayyid - Phenylephrine bolus vs infusion)
30. 7066669 (Graf - Nasal decongestants pharmacology)
31. 22658970 (Sharrock - Metaraminol pharmacology)
32. 25650630 (McDonnell - Vasopressor comparison obstetrics)
33. AIHW. Aboriginal and Torres Strait Islander Health Performance Framework 2020.
34. 27242551 (Anderson - Indigenous health disparities Lancet)